Abbott Laboratories (ABT) volatility increases into Q3 and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbott (ABT) Tops Q3 EPS by 1c; Narrows, Boosts FY16 EPS Outlook
October 19, 2016 7:46 AM EDTAbbott (NYSE: ABT) reported Q3 EPS of $0.59, $0.01 better than the analyst estimate of $0.58. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $5.29 billion.
GUIDANCE:
Abbott sees FY2016 EPS of $2.19 - $2.21, versus prior guidance of $2.14 - $2.24 and... More
